Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma improves Aurum pre-filled syringe packaging
Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

Regulatory
Measurement uncertainty explained – Why it matters more than you think

Measurement uncertainty explained – Why it matters more than you think

Read more
In regulated environments, where decisions often depend on whether a result passes or fails a defined limit, understanding measurement uncertainty becomes critical

Trending Articles

  1. INFORMEX: Sigma-Aldrich sets its sights on biopharma Rapidly growing biologicals sector a major factor behind investment
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. SIRO Clinpharm expands its presence in Asia Launches operations in Malaysia
  4. Maruho Hatsujyo Innovations appoints COO
  5. FDA to review Moderna’s mRNA flu vaccine mRNA-1010 after revised filing The US regulator has accepted Moderna’s amended biologics licence application for its investigational mRNA flu vaccine, mRNA-1010, assigning an August 2026 decision date

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Regulatory
Measurement uncertainty explained – Why it matters more than you think

Measurement uncertainty explained – Why it matters more than you think

In regulated environments, where decisions often depend on whether a result passes or fails a defined limit, understanding measurement uncertainty becomes critical
Regulatory
Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi advances on two fronts: a new Abu Dhabi vaccine innovation centre with AI and mRNA capabilities and UK NICE backing for teplizumab, the first disease-modifying treatment for type 1 diabetes
Manufacturing
RFID brings greater visibility to pharmaceutical supply chains

RFID brings greater visibility to pharmaceutical supply chains

From hospital pharmacies to global distribution networks, RFID is adding a new layer of intelligence to pharmaceutical logistics
Manufacturing
Cogent Skills research exposes specialist skills gaps holding back UK medicines manufacturing SMEs

Cogent Skills research exposes specialist skills gaps holding back UK medicines manufacturing SMEs

The Office for Life Sciences-funded report identifies acute gaps in commercial, R&D and digital competencies, recommending simplified apprenticeships and GMP-ready micro-credentials to support sector growth
Regulatory
Pharmaceutical regulatory update 2026: EU, UK, FDA & global changes explained

Pharmaceutical regulatory update 2026: EU, UK, FDA & global changes explained

EU Pharma Legislation overhaul + Global GMP updates (2026)
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
What Operation TrialBlazer means for CDMOs and CMC strategy

What Operation TrialBlazer means for CDMOs and CMC strategy

The FDA's new framework cuts Phase I data requirements, opens platform manufacturing data reuse and creates a new CRO/CDMO review role as HHS moves to close the gap with China's faster clinical trial pipeline — but how will this affect the pharma sector?
Manufacturing
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Subscribe now